Berninamycin A
(Synonyms: 伯尔尼霉素A) 目录号 : GC13475
A cyclic thiopeptide antibiotic
Cas No.:58798-97-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Berninamycin A is a macrocyclic thiopeptide antibiotic first isolated from S. bernensis [1]. Thiopeptides are sulfur containing highly modified macrocyclic antibiotics with a central pyridine/tetrapyridine/dehydropiperidine ring with up to three thiazole substituents on positions 2, 3 and 6. Thiazole antibiotics thiostrepton behaves as proteasome inhibitor in mammalian tumor cells. Berninamycin showed no proteasome inhibitory activity [2]. It has been reported that the action mode of berninamycin on bacterial protein synthesis was related to that of a dissimilar compound thiostrepton. The antibiotics could bind to the complex of 23S RNA with protein L11 and both affect multiple functions of the ribosomal A site [3]. Berninamycin A was involved in inducing the transcriptional activator TipA in Streptomyces [4].
References:
[1] Lau R C M, Rinehart K L. Berninamycins B, C, and D, minor metabolites from Streptomyces bernensis[J]. The Journal of antibiotics, 1994, 47(12): 1466-1472.
[2] Pandit B, Bhat U G, Gartel A L. Proteasome inhibitory activity of thiazole antibiotics[J]. Cancer biology & therapy, 2011, 11(1): 43-47.
[3] J. Thompson, E. Cundliffe and M. J. R. Stark. The mode of action of berninamycin and mechanism of resistance in the producing organism, Streptomyces bernensis. J.Gen.Microbiol. 128(4), 875-884 (1982).
[4]. M. L. Chiu, M. Folcher, T. Katoh, et al. Broad spectrum thiopeptide recognition specificity of the Streptomyces lividans TipAL protein and its role in regulating gene expression. The Journal of Biological Chemisty 274(29), 20578-20586 (1999).
| Cas No. | 58798-97-3 | SDF | |
| 别名 | 伯尔尼霉素A | ||
| 化学名 | L-threonyl-2-[(1Z)-1-amino-1-propen-1-yl]- 5-methyl-4-oxazolecarbonyl-2,3-didehydroalanyl-3-methyl-L-threonyl-2-(1-aminoethenyl)- 5-methyl-4-oxazolecarbonyl-2,3-didehydroalanyl-6-[2-(1-aminoethenyl)- 4-oxazolyl]-5-(4-carboxy-2-thiazolyl)-2-pyridinecarbony | ||
| Canonical SMILES | O=C(NC(C(NC(C(N)=O)=C)=O)=C)C1=CC=C(C2=NC(C(N[C@]([C@@H](C)O)([H])C(N/C(C3=NC4=C(C)O3)=C\C)=O)=O)=CS2)C(C5=COC(C(NC(C(NC(C6=C(C)OC(C(NC([C@@H](NC(C(NC4=O)=C)=O)C(C)(O)C)=O)=C)=N6)=O)=C)=O)=C)=N5)=N1 | ||
| 分子式 | C51H51N15O15S | 分子量 | 1146.1 |
| 溶解度 | DMF: soluble,DMSO: soluble,Ethanol: moderately soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.8725 mL | 4.3626 mL | 8.7252 mL |
| 5 mM | 0.1745 mL | 0.8725 mL | 1.745 mL |
| 10 mM | 0.0873 mL | 0.4363 mL | 0.8725 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet